Novartis Investigative Site

Bloomfield, New Jersey 07003

0 studies enrolling now · 4 studies all time

What they study most

Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema

Studies at this site

• Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections — Stopped early
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion — Stopped early
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion — Stopped early
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed